Elicio Therapeutics Company Insiders

Elicio Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.9554) % which means that it has lost $0.9554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.8817) %, meaning that it created substantial loss on money invested by shareholders. Elicio Therapeutics' management efficiency ratios could be used to measure how well Elicio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.36 in 2024, whereas Return On Tangible Assets are likely to drop (1.50) in 2024. Other Assets is likely to rise to about 4.2 M in 2024, whereas Total Assets are likely to drop slightly above 20.5 M in 2024. Common Stock Shares Outstanding is likely to drop to about 5.2 M in 2024. Net Loss is likely to drop to about (26.7 M) in 2024

Elicio Therapeutics Workforce Comparison

Elicio Therapeutics Insider Trading

Elicio Therapeutics Notable Stakeholders

The success or failure of an entity such as Elicio Therapeutics often depends on how effective the management is. Elicio Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Elicio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Elicio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Elicio Therapeutics' official financial statements typically reflect Elicio Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Elicio Therapeutics' quantitative information. For example, before you start analyzing numbers published by Elicio accountants, it's essential to understand Elicio Therapeutics' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.

Please note, the imprecision that can be found in Elicio Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Elicio Therapeutics. Check Elicio Therapeutics' Beneish M Score to see the likelihood of Elicio Therapeutics' management manipulating its earnings.

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.